Effect of IQ-1 on the Infarct Size and the Parameters of Cardiodynamic Indicators in the Acute Period after Myocardial Ischemia/Reperfusion in Rats.

The effect of a new JNK inhibitor IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was studied in male Wistar rats in a model of acute myocardial ischemia/reperfusion. Area at risk and myocardial infarct zones were studied in two series of experiments: 16 h after a single dose of IQ-1 (25 mg/kg intraperitoneally during cardiac ischemia) and on day 5 after its course administration (25 mg/kg intraperitoneally during cardiac ischemia and daily over 4 days). On day 5 after ischemia/reperfusion, cardiodynamic indicators were also studied: systolic, end-diastolic, and minimum pressure in the left ventricle, stress-time index, as well as the maximum rates of pressure rise and fall in the left ventricle (+dP/dt and -dP/dt).

Influence of a Decrease in Blood Viscosity on Arterial Pressure in Normotensive and Spontaneously Hypertensive Rats.

We investigated the effect of a decrease in blood viscosity on the mean BP during isovolumic hemodilution and vasodilating activity of the endothelium in normotensive Wistar rats and spontaneously hypertensive rats (SHR). Blood viscosity was reduced by isovolumic hemodilution (replacement of 10% of circulating blood with an equal volume of plasma). Hemodilution caused the same reduction in blood viscosity by 16% in both groups of rats.

Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction.

New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.

[Effect of propranolol in silent myocardial ischemia induced by anthracyclines].

Effect of propranolol on pain-free myocardial ischemia induced by exposure to anthracyclinic antibiotics were assessed by findings from Holter ECG monitoring in 36 patients with acute lymphoblast leukemia against the background of a complete clinical-and-hematological remission. In those patients having received small cumulative doses of anthracyclines (less than 550 mg/m2) in whom depression of ST-segment had an apparent tachydependent character the severity of pain-free ischemia was shown to be alleviated by a 3-week intake of propranolol. Remarkably, those patients with "silent" myocardial ischemia having received high cumulative doses of cytostatics (more than 550 mg/m2) did not derive much benefit from beta-adrenoblocker, which fact might be associated with the presence in this case of ischemic episodes unrelated to tachycardia.

[Receptor regulation of the platelet activity].

Classification of thrombocyte receptors is given, their functions are discussed, and their endogenous and exogenous ligands are considered as potential targets for antithrombotic drugs.